<DOC>
	<DOCNO>NCT01262001</DOCNO>
	<brief_summary>To evaluate safety tolerability FG-3019 subject Idiopathic Pulmonary Fibrosis ( IPF ) efficacy FG-3019 attenuate fibrosis subject .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Study Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>Major Changes : FGCL-3019-049 Protocol Amendment 3 offer long-term extension treatment FG-3019 eligible Cohort 1-EX ( approximately 14 subject ) Cohort 2 ( approximately 28 subject ) subject complete Week 48-EX Week 48 assessment describe Protocol Amendment 2 , respectively . A subject eligible long-term extension treatment investigator , discussion Fibrogen Medical Monitor , believe subject would benefit continued treatment FG-3019 .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Main 1 . Age 35 80 year , inclusive . 2 . Clinical diagnosis IPF high resolution compute tomography ( HRCT ) scan ( case surgical lung biopsy ) reduce lung function ( forced vital capacity ) . 3 . History IPF 5 year duration less . 4 . Evidence progression IPF within last 312 month Cohort 1 , within last 18 month Cohort 2 screening . 5 . Women childbearing potential , men , must willing use medically acceptable method contraception trial 3 month last dose study drug . Main 1 . Women pregnant nursing . 2 . History type lung heart disease medical condition , opinion investigator , would preclude subject 's participation study . 3 . Clinically important abnormal laboratory test . 4 . Upper low respiratory tract infection type within 4 week first screen visit . 5 . Acute exacerbation IPF within 3 month first screen visit . 6 . Use certain medication within 4 week first screen visit . 7 . Receipt investigational drug within 6 week first screen visit . 8 . History cancer type 5 year precede first screen visit , exclude nonmelanomatous skin cancer , localize bladder cancer , situ cervical cancer . 9 . Trauma surgical procedure require hospitalization within 4 week first screen visit . 10 . Planned elective surgery study include 4 week follow final dose study drug . 11 . History allergic anaphylactic reaction human , humanize , chimeric murine monoclonal antibody . 12 . Inability cooperate study personnel history noncompliance medical regimen . 13 . Previous treatment FG3019 .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>